Research Article
BibTex RIS Cite
Year 2020, Volume: 7 Issue: 1, 1 - 4, 29.02.2020

Abstract

References

  • 1. Ulugol A. The endocannabinoid system as a potential therapeutic target for pain modulation. Balkan Med J 2014;31:115-20. 2. Schrot RJ, Hubbard JR. Cannabinoids: medical implications. Ann Med 2016;48:128-41. 3. Sastre-Garriga J, Vila C, Clissold S et al. THC and CBD oromucosal spray (Sativex (R)) in the management of spasticity associated with multiple sclerosis. Expert Rev Neurother 2011;11:627-37. 4. Mallet C, Daulhac L, Bonnefont J et al. Endocannabinoid and serotonergic systems are needed for acetaminophen-induced analgesia. Pain 2008;139:190-200. 5. Rogosch T, Sinning C, Podlewski A et al. Novel bioactive metabolites of dipyrone (metamizol). Bioorgan Med Chem 2012;20:101-7. 6. Crunfli F, Vilela FC, Giusti-Paiva A. Cannabinoid CB1 receptors mediate the effects of dipyrone. Clin Exp Pharmacol P 2015;42:246- 55. 7. Hamza M, Dionne RA. Mechanisms of non-opioid analgesics beyond cyclooxygenase enzyme inhibition. Curr Mol Pharmacol 2009;2:1-14. 8. Paunescu H, Coman OA, Coman L et al. Cannabinoid system and cyclooxygenases inhibitors. J Med Life 2011;4:11-20. 9. Fowler CJ. NSAIDs: endocannabinoid stimulating anti-inflammatory drugs?. Trends Pharmacol Sci 2012;33:468-73. 10. Elmas P, Ulugol A. Involvement of cannabinoid CB1 receptors in the antinociceptive effect of dipyrone. J Neural Transm 2013;120:1533-8. 11. Schlosburg JE, Radanova L, Di Marzo V et al. Evaluation of the endogenous cannabinoid system in mediating the behavioral effects of dipyrone (metamizol) in mice. Behav Pharmacol 2012;23:722-6. 12. Topuz RD, Gunduz O, Karadag HC et al. Endocannabinoid and N-acylethanolamide levels in rat brain and spinal cord following systemic dipyrone and paracetamol administration. Can J Physiol Pharmacol 2019;8:1-7. 13. Saglam G, Gunduz O, Ulugol A. Blockade of cannabinoid CB1 and CB2 receptors does not prevent the antipruritic effect of systemic paracetamol. Acta Neurol Belg 2014;114:307-9. 14. Anikwue R, Huffman JW, Martin ZL et al. Decrease in efficacy and potency of nonsteroidal anti-inflammatory drugs by chronic delta(9)-tetrahydrocannabinol administration. J Pharmacol Exp Ther 2002;303:340-6. 15. Naidu PS, Booker L, Cravatt BF et al. Synergy between enzyme inhibitors of fatty acid amide hydrolase and cyclooxygenase in visceral nociception. J Pharmacol Exp Ther 2009;329:48-56. 16. Zimmermann M. Ethical guidelines for investigations of experimental pain in conscious animals. Pain 1983;16:109-10. 17. Ulugol A, Ozyigit F, Yesilyurt O et al. The additive antinociceptive interaction between WIN 55,212-2, a cannabinoid agonist, and ketorolac. Anesth Analg 2006;102:443-7. 18. Gencer A, Gunduz O, Ulugol A. Involvement of descending serotonergic and noradrenergic systems and their spinal receptor subtypes in the antinociceptive effect of dipyrone. Drug Res 2015;65:645-9. 19. Yilmaz I, Ulugol A. The effect of nitric oxide synthase inhibitors on the development of analgesic tolerance to dipyrone in mice. Int J Neurosci 2009;119:755-64. 20. Ertin IH, Gunduz O, Ulugol A. Contribution of nociceptin/orphanin FQ receptors to the anti-nociceptive and hypothermic effects of dipyrone. Acta Neuropsychiatr 2015;27:48-52. 21. Vane J, Botting R. Inflammation and the mechanism of action of antiinflammatory drugs. Faseb Journal 1987;1:89-96. 22. Guhring H, Hamza M, Sergejeva M et al. A role for endocannabinoids in indomethacin-induced spinal antinociception. Eur J Pharmacol 2002;454:153-63. 23. Ortiz MI, Granados-Soto V, Castaneda-Hernandez G. The NO-cGMP-K+ channel pathway participates in the antinociceptive effect of diclofenac, but not of indomethacin. Pharmacol Biochem Behav 2003;76:187-95. 24. Silva LCR, Romero TRL, Guzzo LS et al. Participation of cannabinoid receptors in peripheral nociception induced by some NSAIDs. Braz J Med Biol Res 2012;45:1240-3.

CANNABINOID RECEPTORS ARE NOT INVOLVED IN ANTINOCICEPTION INDUCED BY SYSTEMIC DICLOFENAC IN MICE

Year 2020, Volume: 7 Issue: 1, 1 - 4, 29.02.2020

Abstract

Aims: It has been long suspected that the cannabinoid system participates in the antinociceptive effects of nonsteroidal anti-inflammatory drugs. We studied the possible effects of cannabinoid receptor antagonism on diclofenac-induced antinociception
in the writhing test in mice. Methods: In our study, male BALB/c mice, weighing 20-30 g, were used. Writhing responses were
produced by intraperitoneal injection of 0.6% acetic acid. Different doses of diclofenac (3, 10, 30 mg/kg, i.p.) were tested, then
the influence of AM-251 (1 mg/kg, i.p.), a cannabinoid CB1 receptor antagonist and AM-630 (3 mg/kg, i.p.), a cannabinoid
CB2 receptor antagonist on the antinociceptive effects of diclofenac was studied. Results: Diclofenac administration elicited a
significant, dose-dependent antinociceptive response; however, neither the cannabinoid CB1 receptor antagonist AM-251 nor
the cannabinoid CB2 receptor antagonist AM-630 had any influence on the antinociceptive effect of diclofenac. Conclusion:
Iinhibition of cannabinoid receptors does not contribute to the antinociceptive action of systemic diclofenac. Further studies
are needed to explain the antinociceptive mechanism of diclofenac. Keywords: AM-251, AM-630, antinociception, cannabinoid
receptors, diclofenac

References

  • 1. Ulugol A. The endocannabinoid system as a potential therapeutic target for pain modulation. Balkan Med J 2014;31:115-20. 2. Schrot RJ, Hubbard JR. Cannabinoids: medical implications. Ann Med 2016;48:128-41. 3. Sastre-Garriga J, Vila C, Clissold S et al. THC and CBD oromucosal spray (Sativex (R)) in the management of spasticity associated with multiple sclerosis. Expert Rev Neurother 2011;11:627-37. 4. Mallet C, Daulhac L, Bonnefont J et al. Endocannabinoid and serotonergic systems are needed for acetaminophen-induced analgesia. Pain 2008;139:190-200. 5. Rogosch T, Sinning C, Podlewski A et al. Novel bioactive metabolites of dipyrone (metamizol). Bioorgan Med Chem 2012;20:101-7. 6. Crunfli F, Vilela FC, Giusti-Paiva A. Cannabinoid CB1 receptors mediate the effects of dipyrone. Clin Exp Pharmacol P 2015;42:246- 55. 7. Hamza M, Dionne RA. Mechanisms of non-opioid analgesics beyond cyclooxygenase enzyme inhibition. Curr Mol Pharmacol 2009;2:1-14. 8. Paunescu H, Coman OA, Coman L et al. Cannabinoid system and cyclooxygenases inhibitors. J Med Life 2011;4:11-20. 9. Fowler CJ. NSAIDs: endocannabinoid stimulating anti-inflammatory drugs?. Trends Pharmacol Sci 2012;33:468-73. 10. Elmas P, Ulugol A. Involvement of cannabinoid CB1 receptors in the antinociceptive effect of dipyrone. J Neural Transm 2013;120:1533-8. 11. Schlosburg JE, Radanova L, Di Marzo V et al. Evaluation of the endogenous cannabinoid system in mediating the behavioral effects of dipyrone (metamizol) in mice. Behav Pharmacol 2012;23:722-6. 12. Topuz RD, Gunduz O, Karadag HC et al. Endocannabinoid and N-acylethanolamide levels in rat brain and spinal cord following systemic dipyrone and paracetamol administration. Can J Physiol Pharmacol 2019;8:1-7. 13. Saglam G, Gunduz O, Ulugol A. Blockade of cannabinoid CB1 and CB2 receptors does not prevent the antipruritic effect of systemic paracetamol. Acta Neurol Belg 2014;114:307-9. 14. Anikwue R, Huffman JW, Martin ZL et al. Decrease in efficacy and potency of nonsteroidal anti-inflammatory drugs by chronic delta(9)-tetrahydrocannabinol administration. J Pharmacol Exp Ther 2002;303:340-6. 15. Naidu PS, Booker L, Cravatt BF et al. Synergy between enzyme inhibitors of fatty acid amide hydrolase and cyclooxygenase in visceral nociception. J Pharmacol Exp Ther 2009;329:48-56. 16. Zimmermann M. Ethical guidelines for investigations of experimental pain in conscious animals. Pain 1983;16:109-10. 17. Ulugol A, Ozyigit F, Yesilyurt O et al. The additive antinociceptive interaction between WIN 55,212-2, a cannabinoid agonist, and ketorolac. Anesth Analg 2006;102:443-7. 18. Gencer A, Gunduz O, Ulugol A. Involvement of descending serotonergic and noradrenergic systems and their spinal receptor subtypes in the antinociceptive effect of dipyrone. Drug Res 2015;65:645-9. 19. Yilmaz I, Ulugol A. The effect of nitric oxide synthase inhibitors on the development of analgesic tolerance to dipyrone in mice. Int J Neurosci 2009;119:755-64. 20. Ertin IH, Gunduz O, Ulugol A. Contribution of nociceptin/orphanin FQ receptors to the anti-nociceptive and hypothermic effects of dipyrone. Acta Neuropsychiatr 2015;27:48-52. 21. Vane J, Botting R. Inflammation and the mechanism of action of antiinflammatory drugs. Faseb Journal 1987;1:89-96. 22. Guhring H, Hamza M, Sergejeva M et al. A role for endocannabinoids in indomethacin-induced spinal antinociception. Eur J Pharmacol 2002;454:153-63. 23. Ortiz MI, Granados-Soto V, Castaneda-Hernandez G. The NO-cGMP-K+ channel pathway participates in the antinociceptive effect of diclofenac, but not of indomethacin. Pharmacol Biochem Behav 2003;76:187-95. 24. Silva LCR, Romero TRL, Guzzo LS et al. Participation of cannabinoid receptors in peripheral nociception induced by some NSAIDs. Braz J Med Biol Res 2012;45:1240-3.
There are 1 citations in total.

Details

Primary Language English
Subjects Clinical Sciences
Journal Section Research Article
Authors

Beiza Chatzisali This is me 0000-0002-9995-0414

Tolga Gaş This is me

Hilmi Kılgın This is me

Kübra Duvan Aydemir This is me

Dilşat Erümit This is me

Ruhan Deniz Topuz This is me

Ahmet Ulugöl This is me

Publication Date February 29, 2020
Submission Date October 24, 2019
Published in Issue Year 2020 Volume: 7 Issue: 1

Cite

APA Chatzisali, B., Gaş, T., Kılgın, H., Aydemir, K. D., et al. (2020). CANNABINOID RECEPTORS ARE NOT INVOLVED IN ANTINOCICEPTION INDUCED BY SYSTEMIC DICLOFENAC IN MICE. Turkish Medical Student Journal, 7(1), 1-4.
AMA Chatzisali B, Gaş T, Kılgın H, Aydemir KD, Erümit D, Topuz RD, Ulugöl A. CANNABINOID RECEPTORS ARE NOT INVOLVED IN ANTINOCICEPTION INDUCED BY SYSTEMIC DICLOFENAC IN MICE. TMSJ. February 2020;7(1):1-4.
Chicago Chatzisali, Beiza, Tolga Gaş, Hilmi Kılgın, Kübra Duvan Aydemir, Dilşat Erümit, Ruhan Deniz Topuz, and Ahmet Ulugöl. “CANNABINOID RECEPTORS ARE NOT INVOLVED IN ANTINOCICEPTION INDUCED BY SYSTEMIC DICLOFENAC IN MICE”. Turkish Medical Student Journal 7, no. 1 (February 2020): 1-4.
EndNote Chatzisali B, Gaş T, Kılgın H, Aydemir KD, Erümit D, Topuz RD, Ulugöl A (February 1, 2020) CANNABINOID RECEPTORS ARE NOT INVOLVED IN ANTINOCICEPTION INDUCED BY SYSTEMIC DICLOFENAC IN MICE. Turkish Medical Student Journal 7 1 1–4.
IEEE B. Chatzisali, “CANNABINOID RECEPTORS ARE NOT INVOLVED IN ANTINOCICEPTION INDUCED BY SYSTEMIC DICLOFENAC IN MICE”, TMSJ, vol. 7, no. 1, pp. 1–4, 2020.
ISNAD Chatzisali, Beiza et al. “CANNABINOID RECEPTORS ARE NOT INVOLVED IN ANTINOCICEPTION INDUCED BY SYSTEMIC DICLOFENAC IN MICE”. Turkish Medical Student Journal 7/1 (February 2020), 1-4.
JAMA Chatzisali B, Gaş T, Kılgın H, Aydemir KD, Erümit D, Topuz RD, Ulugöl A. CANNABINOID RECEPTORS ARE NOT INVOLVED IN ANTINOCICEPTION INDUCED BY SYSTEMIC DICLOFENAC IN MICE. TMSJ. 2020;7:1–4.
MLA Chatzisali, Beiza et al. “CANNABINOID RECEPTORS ARE NOT INVOLVED IN ANTINOCICEPTION INDUCED BY SYSTEMIC DICLOFENAC IN MICE”. Turkish Medical Student Journal, vol. 7, no. 1, 2020, pp. 1-4.
Vancouver Chatzisali B, Gaş T, Kılgın H, Aydemir KD, Erümit D, Topuz RD, Ulugöl A. CANNABINOID RECEPTORS ARE NOT INVOLVED IN ANTINOCICEPTION INDUCED BY SYSTEMIC DICLOFENAC IN MICE. TMSJ. 2020;7(1):1-4.